The protein encoded by this gene is a lysosomalcysteine protease composed of a dimer of disulfide-linked heavy and light chains, both produced from a single protein precursor. It is a member of the peptidase C1 family. At least five transcript variants encoding the same protein have been found for this gene.
A wide array of diseases result in elevated levels of cathepsin B, which causes numerous pathological processes including cell death, inflammation, and production of toxic peptides. Focusing on neurological diseases, cathepsin B gene knockout studies in an epileptic rodent model have shown cathepsin B causes a significant amount of the apoptotic cell death that occurs as a result of inducing epilepsy. Cathepsin B inhibitor treatment of rats in which a seizure was induced resulted in improved neurological scores, learning ability and much reduced neuronal cell death and pro-apoptotic cell death peptides.  Similarly, cathepsin B gene knockout and cathepsin B inhibitor treatment studies in traumatic brain injury mouse models have shown cathepsin B to be key to causing the resulting neuromuscular dysfunction, memory loss, neuronal cell death and increased production of pro-necrotic and pro-apoptotic cell death peptides.  In ischemic non-human primate and rodent models, cathepsin B inhibitor treatment prevented a significant loss of brain neurons, especially in the hippocampus.  In a streptococcus pneumoniae meningitis rodent model, cathepsin B inhibitor treatment greatly improved the clinical course of the infection and reduced brain inflammation and inflammatory Interleukin-1beta (IL1-beta) and tumor necrosis factor-alpha (TNFalpha). In a transgenic Alzheimer's disease (AD) animal model expressing human amyloid precursor protein (APP) containing the wild-type beta-secretase site sequence found in most AD patients or in guinea pigs, which are a natural model of human wild-type APP processing, genetically deleting the cathepsin B gene or chemically inhibiting cathepsin B brain activity resulted in a significant improvement in the memory deficits that develop in such mice and reduces levels of neurotoxic full-length Abeta(1-40/42) and the particularly pernicious pyroglutamate Abeta(3-40/42), which are thought to cause the disease.  In a non-transgenic senescence-accelerated mouse strain, which also has APP containing the wild-type beta-secretase site sequence, treatment with bilobalide, which is an extract of Ginko biloba leaves, also lowered brain Abeta by inhibiting cathepsin B.  Moreover, siRNA silencing or chemically inhibiting cathepsin B in primary rodent hippocampal cells or bovine chromaffin cells, which have human wild-type beta-secretase activity, reduces secretion of Abeta by the regulated secretory pathway. 
^Housewert, M.; Pennacchio, L.A.; Vilaythong, A.; Peters, C.; Noebels, J.L.; Myers, R.M. (2003). "Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1)". J Neurobiol56: 315-27.
^Ni, H.; Ren, S.Y.; Zhang, L.L.; Sun, Q.; Tian, T.; Feng, X. (2013). "Expression profiles of hippocampal regenerative sprouting-related genes and their regulation by E-64d in a developmental rat model of penicillin-induced recurrent epilepticus". Toxicol Lett217 (2): 162-9. PMID23266720.
^Hook, G.; Yu, J.; Sipes, N.; Pierschbacher, M.; Hook, V.; Kindy, M.S. (2013). "The Cysteine Protease Cathepsin B is a Key Drug Target and Cysteine Protease Inhibitors are Potential Therapeutics for Traumatic Brain Injury". J Neurotrauma31: 515-529. PMID24083575.
^Luo, C.L.; Chen, X.P.; Yang, R.; Sun, Y.X.; Li, Q.Q.; Bao, H.J.; Cao, Q.Q.; Ni, H.; Qin, Z.H.; Tao, L.Y. (2010). "Cathepsin B contributes to traumatic brain injury-induced cell death through a mitochondria-mediated apoptotic pathway". J Neurosci Res88 (13): 2847–58. PMID20653046.
^Yoshida, M.; Yamashima, T.; Zhao, L.; Tsuchiya, K.; Kohda, Y.; Tonchev, A.B.; Matsuda, M.; Kominami, E. (2002). "Primate neurons show different vulnerability to transient ischemia and response to cathepsin inhibition". Acta Neuropathol (Berl)104 (3): 267–72. PMID12172912.
^Tsuchiya, K.; Kohda, Y.; Yoshida, M.; Zhao, L.; Ueno, T.; Yamashita, J.; Yoshioka, J.; Kominami, E. et al. (1999). "Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors". Exp Neurol155 (2): 187–94. PMID10072294.|displayauthors= suggested (help)
^Tsubokawa, T.; Yamaguchi-Okada, M.; Calvert, J.W.; Solaroglu, I.; Shimamura, N.; Yata, K.; Zhang, J.H. (2006). "Neurovascular and neuronal protection by E64d after focal cerebral ischemia in rats". J Neurosci Res84 (4): 832–40. PMID16802320.
^Hoegen, T.; Tremel, N.; Klein, M.; Angele, B.; Wagner, H.; Kirschning, C.; Pfister, H.W.; Fontana, A.; Hammerschmidt, S.; Koedel, U. (2011). "The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release". J Immunol187 (10): 5440–51. PMID22003197.
^Hook, V.Y.; Kindy, M.; Hook, G. (2008). "Inhibitors of cathepsin B improve memory and reduce Abeta in transgenic Alzheimer's Disease mice expressing the wild-type, but not the Swedish mutant, beta -secretase APP site". J Biol Chem283 (12): 7745–7753. PMID18184658.
^Hook, V.; Kindy, M.; Hook, G. (2007). "Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease". Biol Chem388 (2): 247–52. PMID17261088.
^Hook, G.; Hook, V.Y.; Kindy, M. "Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics". Biol Chem388 (9): 979–83. PMID17696783.
^Hook, V.Y.; Kindy, M.; Reinheckel, T.; Peters, C.; Hook, G. (2009). "Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein". Biochem Biophys Res Commun386 (2): 284–8. PMID19501042.
^Hook, G.; Hook, V.; Kindy, M. (2011). "The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-beta and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, beta-Secretase Activity". J Alzheimers Dis26 (2): 387–408. PMID21613740.
^Kindy, M.S.; Yu, J.; Zhu, H.; El-Amouri, S.S.; Hook, V.; Hook, G.R. (2012). "Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic Alzheimer's Disease Mouse Model Expressing AbetaPP Containing the Wild-Type beta-Secretase Site Sequence". J Alzheimers Dis29 (4): 827–40. PMID22337825.
^Hook, G.; Yu, J.; Toneff, T.; Kindy, M.; Hook, V. (2014). "Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic". J Alzheimers Dis41 (1): 129–49. PMID24595198.
^Hook, V.; Tonneff, T.; Bogyo, M.; Medzihradszky, K.F.; Nevenu, J.; Lane, W.; Hook, G.; Reisine, T. (2005). "Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer’s disease". Biological Chemistry386: 931–940. PMID16164418.
^Klein, D.M.; Felsentein, K.M.; Brenneman, D.E. (2009). "Cathepsins B and L differentially regulate amyloid precursor protein processing". J Pharmacol Exp Ther329 (3): 813–21. PMID19064719.
^ abPavlova A, Björk I (September 2003). "Grafting of features of cystatins C or B into the N-terminal region or second binding loop of cystatin A (stefin A) substantially enhances inhibition of cysteine proteinases". Biochemistry42 (38): 11326–33. doi:10.1021/bi030119v. PMID14503883.
^Mai J, Finley RL, Waisman DM, Sloane BF (April 2000). "Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells". J. Biol. Chem.275 (17): 12806–12. doi:10.1074/jbc.275.17.12806. PMID10777578.
^Estrada S, Nycander M, Hill NJ, Craven CJ, Waltho JP, Björk I (May 1998). "The role of Gly-4 of human cystatin A (stefin A) in the binding of target proteinases. Characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L". Biochemistry37 (20): 7551–60. doi:10.1021/bi980026r. PMID9585570.